What happened
Travere Therapeutics, Inc. (NASDAQ: TVTX) said Chief Executive Officer and director Eric M. Dube sold 243,735 shares on 2026-10-15. The filing puts the sale price at $52.97 to $55.02 per share, or about $13.12 million total. It also says the shares sold came from stock options exercised the same day. After the sale, Dube reported 432,886 shares. The filing checked the box for a Rule 10b5-1 trading plan and says the plan was adopted on June 16, 2026.
The form also lists 43,735 option shares at $26.88 and 200,000 option shares at $8.93. It then reports three sales of 128,065 shares, 37,270 shares and 78,400 shares, with weighted average prices of $52.9672, $54.1997 and $55.0179. The total across the three sales is 243,735 shares.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 243,735 shares | SEC Form 4 | |
| Sale value | about $13.12 million | SEC Form 4 | |
| Shares held after sale | 432,886 shares | SEC Form 4 | |
| Sale price range | $52.97 to $55.02 per share | SEC Form 4 | |
| Sale block vs. pre-sale holding | 36.0% | Calculated from SEC Form 4 |
Read more: Travere Therapeutics (TVTX) stock analysis and investment case
Why it matters
The filing is mixed for investors because it shows Eric M. Dube selling a large block under a Rule 10b5-1 plan.
OptimistFi's calculation puts the 243,735 shares at 36.0% of the 676,621-share holding before the trade. That leaves the insider with 432,886 shares after the sale, which is the new ownership baseline. The report also confirms direct ownership after the sale.
The weighted-average sale prices are above the two exercise prices. That matters because the report ties the sale to exercised awards.
The main caveat is the filing's own Rule 10b5-1 language, which can point to planned liquidity rather than a fresh change in outlook. The same filing also ties the sale to exercises of 43,735 shares and 200,000 shares.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
The $26.88 option was fully vested and exercisable, and its expiration date is 01/21/2031. The $8.93 option has an expiration date of 01/31/2034, with one-fourth vested on 01/31/2025 and the balance vesting in 36 equal monthly installments. The second award's vesting schedule further extends the timeline.
The reported awards remain part of the filing's current ownership picture after the sale.
More from OptimistFi
- TVTX stock: the Travere Therapeutics thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
Sources
- SEC Form 4 — Eric M. Dube's Form 4 filed on 2026-10-19.
Read the full OptimistFi thesis on Travere Therapeutics, Inc.: https://optimistfi.com/stocks/TVTX
See what would break the Travere Therapeutics, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Travere Therapeutics, Inc. investment case, its status and the next test to watch live on the Travere Therapeutics, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
